AgeneBio, founded in Baltimore, United States, is a neuroscience pharmaceutical company dedicated to discovering and developing innovative therapeutics for patients at risk of neurological and psychiatric conditions. The company's core mission is to improve the lives of patients, their families, and society by addressing diseases that impact memory. AgeneBio's product pipeline includes AGB101, a treatment for Mild Cognitive Impairment (MCI) due to Alzheimer's Disease, and a novel GABA(A) α5 discovery program targeting memory-related disorders.
Notable figures associated with AgeneBio include experts in neuroscience and pharmaceutical development, though specific names are not provided. The company has made significant strides in its field, particularly with the development of AGB101, which has shown promise in clinical trials. AgeneBio's impact is marked by its commitment to addressing critical gaps in the treatment of memory-impacting diseases, positioning itself as a key player in the neuroscience pharmaceutical industry.
